BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 9592806)

  • 1. [Involvement of cytochromeP4503A4 in the metabolism of haloperidol and bromperidol].
    Furukori H
    Nihon Shinkei Seishin Yakurigaku Zasshi; 1998 Feb; 18(1):9-14. PubMed ID: 9592806
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of itraconazole on the steady-state plasma concentrations of bromperidol and reduced bromperidol in schizophrenic patients.
    Furukori H; Kondo T; Yasui N; Otani K; Tokinaga N; Nagashima U; Kaneko S; Inoue Y
    Psychopharmacology (Berl); 1999 Jul; 145(2):189-92. PubMed ID: 10463320
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of itraconazole on the steady-state plasma concentrations of haloperidol and its reduced metabolite in schizophrenic patients: in vivo evidence of the involvement of CYP3A4 for haloperidol metabolism.
    Yasui N; Kondo T; Otani K; Furukori H; Mihara K; Suzuki A; Kaneko S; Inoue Y
    J Clin Psychopharmacol; 1999 Apr; 19(2):149-54. PubMed ID: 10211916
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation between steady-state plasma concentrations (Css) of bromperidol and haloperidol.
    Yasui N; Otani K; Kondo T; Suzuki A; Furukori H; Kaneko S; Inoue Y
    Prog Neuropsychopharmacol Biol Psychiatry; 1998 Apr; 22(3):485-92. PubMed ID: 9612845
    [TBL] [Abstract][Full Text] [Related]  

  • 5. No interaction between desipramine and bromperidol.
    Suzuki A; Otani K; Ishida M; Yasui N; Kondo T; Mihara K; Kaneko S; Inoue Y
    Prog Neuropsychopharmacol Biol Psychiatry; 1996 Oct; 20(7):1265-71. PubMed ID: 8938825
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined effects of itraconazole and CYP2D6*10 genetic polymorphism on the pharmacokinetics and pharmacodynamics of haloperidol in healthy subjects.
    Park JY; Shon JH; Kim KA; Jung HJ; Shim JC; Yoon YR; Cha IJ; Shin JG
    J Clin Psychopharmacol; 2006 Apr; 26(2):135-42. PubMed ID: 16633141
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum concentrations of clozapine and N-desmethylclozapine are unaffected by the potent CYP3A4 inhibitor itraconazole.
    Raaska K; Neuvonen PJ
    Eur J Clin Pharmacol; 1998 Apr; 54(2):167-70. PubMed ID: 9626923
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interaction between carbamazepine and bromperidol.
    Otani K; Ishida M; Yasui N; Kondo T; Mihara K; Suzuki A; Furukori H; Kaneko S; Inoue Y
    Eur J Clin Pharmacol; 1997; 52(3):219-22. PubMed ID: 9218929
    [TBL] [Abstract][Full Text] [Related]  

  • 9. No pharmacokinetic but pharmacodynamic interactions between cisapride and bromperidol or haloperidol.
    Mihara K; Otani K; Yasui N; Ishida M; Kondo T; Suzuki A; Furukori H; Nagashima U; Kaneko S; Inoue Y
    Ther Drug Monit; 1999 Jun; 21(3):297-300. PubMed ID: 10365640
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of various factors including the CYP2D6 genotype and coadministration of flunitrazepam on the steady-state plasma concentrations of bromperidol and its reduced metabolite.
    Suzuki A; Otani K; Mihara K; Yasui N; Kondo T; Tokinaga N; Furukori H; Kaneko S; Inoue Y; Hayashi K
    Psychopharmacology (Berl); 1998 Feb; 135(4):333-7. PubMed ID: 9539256
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CYP3A is responsible for N-dealkylation of haloperidol and bromperidol and oxidation of their reduced forms by human liver microsomes.
    Tateishi T; Watanabe M; Kumai T; Tanaka M; Moriya H; Yamaguchi S; Satoh T; Kobayashi S
    Life Sci; 2000 Nov; 67(24):2913-20. PubMed ID: 11133003
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytochrome P450 3A inhibitor itraconazole affects plasma concentrations of risperidone and 9-hydroxyrisperidone in schizophrenic patients.
    Jung SM; Kim KA; Cho HK; Jung IG; Park PW; Byun WT; Park JY
    Clin Pharmacol Ther; 2005 Nov; 78(5):520-8. PubMed ID: 16321618
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects and side-effects of bromperidol in comparison with other antipsychotic drugs.
    Woggon B
    Acta Psychiatr Belg; 1978; 78(1):155-72. PubMed ID: 347878
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic parameters of bromperidol in Korean subjects.
    Lee SY; Kim YG; Kim HG; Kim JW
    Hum Psychopharmacol; 2006 Aug; 21(6):409-12. PubMed ID: 16915578
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lack of CYP3A4 inhibition by grapefruit juice and ketoconazole upon clozapine administration in vivo.
    Lane HY; Chiu CC; Kazmi Y; Desai H; Lam YW; Jann MW; Chang WH
    Drug Metabol Drug Interact; 2001; 18(3-4):263-78. PubMed ID: 11791889
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduced haloperidol does not interfere with the antipsychotic activity of haloperidol in the treatment of acute schizophrenia.
    Ulrich S; Neuhof S; Braun V; Meyer FP
    Int Clin Psychopharmacol; 1999 Jul; 14(4):219-28. PubMed ID: 10468314
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Studies on the metabolism of haloperidol (HP): the role of CYP3A in the production of the neurotoxic pyridinium metabolite HPP+ found in rat brain following ip administration of HP.
    Igarashi K; Kasuya F; Fukui M; Usuki E; Castagnoli N
    Life Sci; 1995 Nov; 57(26):2439-46. PubMed ID: 8847965
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of prolactin concentrations between haloperidol and bromperidol treatments in schizophrenic patients.
    Yasui-Furukori N; Kondo T; Suzuki A; Mihara K; Kaneko S; Otani K
    Prog Neuropsychopharmacol Biol Psychiatry; 2002 Apr; 26(3):575-8. PubMed ID: 11999910
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased plasma concentrations of bromperidol and its reduced metabolite with levomepromazine, but not with thioridazine.
    Suzuki A; Otani K; Ishida M; Yasui N; Kondo T; Mihara K; Kaneko S; Inoue Y; Shibata M; Ikeda K
    Ther Drug Monit; 1997 Jun; 19(3):261-4. PubMed ID: 9200764
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Histamine H1-receptor antagonists, promethazine and homochlorcyclizine, increase the steady-state plasma concentrations of haloperidol and reduced haloperidol.
    Suzuki A; Yasui-Furukori N; Mihara K; Kondo T; Furukori H; Inoue Y; Kaneko S; Otani K
    Ther Drug Monit; 2003 Apr; 25(2):192-6. PubMed ID: 12657913
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.